Nanobiotix S.A.
NBTXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeNanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. With a market capitalization of $1.86B, it sits in small-cap territory. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Market Cap
$1.86B
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
252.23
EPS (TTM)
$-0.58
EPS (Fwd)
$0.15
ROE
—
ROA
-10.1%
Cash
$52.8M
Total Debt
$95.3M
Free CF
-$7.9M
52W Change
707.9%
Annual Financials
Cash vs Debt
On the balance sheet, NBTX has $52.8M in cash with $95.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$7.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
NBTX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NBTX.